Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KIMS-005
- Development stage
- Preclinical
- Lead developer
- Kims Pharmaceutical
01
Overview
KIMS-005 is a biologic therapeutic candidate currently in preclinical development by Kims Pharmaceutical. It is being investigated for its potential applications in regenerative medicine, specifically targeting tissue regeneration. As of the current pipeline status, specific details regarding its molecular target, mechanism of action, or the specific type of tissue it is intended to regenerate (e.g., musculoskeletal, dermal, or neural) have not been publicly disclosed. The program is categorized under the company's research-stage assets focused on developing novel biologic treatments for degenerative conditions.
Beyond the preview
Go deeper on KIMS-005.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KIMS-005.